Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. Prevention of exacerbations is fundamental to COPD management. Methods: The RETRIEVE study was a multicenter, 7-year retrospective study (NCT03858348) of patients with spirometry confirmation of COPD, who received LABA/ICS for at least 1 year and either continued or escalated to open triple therapy, according to their physicians’ judgment. In this post hoc analysis, we explored exacerbation rate and lung function pre- and post-pneumococcal vaccination in a real-world setting. Results: Among 466 COPD patients, 48.1% received LABA/ICS for a mean 32 months, while 51.9% received LABA/ICS for a mean 21 months and then escalated to open triple therapy. Patients treated solely with LABA/ICS presented a significant reduction in COPD exacerbations (incidence rate ratio 0.66, 95% confidence interval [0.56, 0.78]) and related hospitalizations (0.43 [0.25, 0.72]) after pneumococcal vaccination compared to pre-vaccination. High-risk patients, who ultimately escalated to triple therapy, presented no reduction in exacerbations post-vaccination compared to pre-vaccination, and their airflow obstruction tended to deteriorate over time post-vaccination while they received LABA/ICS. However, after escalation to open triple therapy, there was significant reduction in exacerbations (0.78 [0.66, 0.94]) and related hospitalizations (0.41 [0.26, 0.66]) post-vaccination compared to pre-vaccination. Pneumococcal vaccination rates increased from 2012 to 2018 in our study, exceeding 90% from 2015 onward. Preserved lung function potentially delayed vaccination. Conclusion: This post hoc analysis of the RETRIEVE real-world study highlights the importance of appropriate, personalized maintenance COPD treatment, along with pneumococcal vaccination, for the prevention of COPD exacerbations.
References
1.
Safiri
S
, Carson-Chahhoud
K
, Noori
M
, Nejadghaderi
SA
, Sullman
MJM
, Ahmadian Heris
J
, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019
. BMJ
. 2022
;378
:e069679
. 2.
Dobler
CC
, Morrow
AS
, Beuschel
B
, Farah
MH
, Majzoub
AM
, Wilson
ME
, et al. Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis
. Ann Intern Med
. 2020
;172
(6
):413
–22
. 3.
Papadopoulou
E
, Hansel
J
, Lazar
Z
, Kostikas
K
, Tryfon
S
, Vestbo
J
, et al. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis
. Eur Respir Rev
. 2023
;32
(167
):220141
. 4.
Papadopoulou
E
, Bin Safar
S
, Khalil
A
, Hansel
J
, Wang
R
, Corlateanu
A
, et al. Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis
. Eur Respir Rev
. 2024
;33
(171
):230151
. 5.
Soler-Cataluña
JJ
, Martínez-García
MA
, Román Sánchez
P
, Salcedo
E
, Navarro
M
, Ochando
R
. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
. Thorax
. 2005
;60
(11
):925
–31
. 6.
Anzueto
A
. Impact of exacerbations on COPD
. Eur Respir Rev
. 2010
;19
(116
):113
–8
. 7.
2024 GOLD Report - Global Initiative for Chronic Obstructive Lung Disease - GOLD (goldcopd.org) Date last accessed: 16 April 2024.
8.
Lipson
DA
, Barnhart
F
, Brealey
N
, Brooks
J
, Criner
GJ
, Day
NC
, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD
. N Engl J Med
. 2018
;378
(18
):1671
–80
. 9.
Rabe
KF
, Martinez
FJ
, Ferguson
GT
, Wang
C
, Singh
D
, Wedzicha
JA
, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD
. N Engl J Med
. 2020
;383
(1
):35
–48
. 10.
Nannini
LJ
, Poole
P
, Milan
SJ
, Kesterton
A
. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
. Cochrane Database Syst Rev
. 2013
;2013
(8
):CD006826
. 11.
Nannini
LJ
, Lasserson
TJ
, Poole
P
. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
. Cochrane Database Syst Rev
. 2012
;2012
(9
):CD006829
. 12.
Anzueto
A
, Miravitlles
M
. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development
. Respir Res
. 2020
;21
(1
):199
. 13.
Papi
A
, Bellettato
CM
, Braccioni
F
, Romagnoli
M
, Casolari
P
, Caramori
G
, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations
. Am J Respir Crit Care Med
. 2006
;173
(10
):1114
–21
. 14.
Sethi
S
, Murphy
TF
. Infection in the pathogenesis and course of chronic obstructive pulmonary disease
. N Engl J Med
. 2008
;359
(22
):2355
–65
. 15.
Centers for Disease Control and Prevention. Recommended Vaccines for Adults: Lung Disease including Asthma or COPD, 2023, available here: Recommended Vaccines for Adults|CDC (last accessed on 16 April, 2024)
16.
Simon
S
, Joean
O
, Welte
T
, Rademacher
J
. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus
. Eur Respir Rev
. 2023
;32
(169
):230034
. 17.
Tryfon
S
, Papadopoulou
E
, Bertoli
M
, Exarchos
K
, Ginis
A
, Kostikas
K
. Lung function and exacerbations in patients with COPD escalated to triple therapy: the RETRIEVE real-world study
. Respirology
. 2023
;28
(12
):1166
–9
. 18.
von Elm
E
, Altman
DG
, Egger
M
, Pocock
SJ
, Gøtzsche
PC
, Vandenbroucke
JP
, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
. BMJ
. 2007
;335
(7624
):806
–8
. 19.
Walters
JA
, Tang
JN
, Poole
P
, Wood-Baker
R
. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
. Cochrane Database Syst Rev
. 2017
;1
(1
):CD001390
. 20.
Ignatova
GL
, Avdeev
SN
, Antonov
VN
. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study
. Sci Rep
. 2021
;11
(1
):15948
. 21.
Venkitakrishnan
R
, Vijay
A
, Augustine
J
, Ramachandran
D
, Cleetus
M
, Nirmal
AS
, et al. Hospitalisation outcomes in pneumococcal-vaccinated versus -unvaccinated patients with exacerbation of COPD: results from the HOPE COPD Study
. ERJ Open Res
. 2023
;9
(3
):00476-2022
. 22.
Saiphoklang
N
, Phadungwatthanachai
J
. Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease
. Hum Vaccin Immunother
. 2022
;18
(6
):2102840
. 23.
Fekete
M
, Pako
J
, Nemeth
AN
, Tarantini
S
, Varga
JT
. Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations
. J Thorac Dis
. 2020
;12
(8
):4233
–42
. 24.
Clutterbuck
EA
, Lazarus
R
, Yu
LM
, Bowman
J
, Bateman
EAL
, Diggle
L
, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells
. J Infect Dis
. 2012
;205
(9
):1408
–16
. 25.
Pollard
AJ
, Perrett
KP
, Beverley
PC
. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines
. Nat Rev Immunol
. 2009
;9
(3
):213
–20
. 26.
Huang
L
, Wasserman
M
, Grant
L
, Farkouh
R
, Snow
V
, Arguedas
A
, et al. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States
. Vaccine
. 2022
;40
(33
):4700
–8
. 27.
Ladhani
SN
, Collins
S
, Djennad
A
, Sheppard
CL
, Borrow
R
, Fry
NK
, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study
. Lancet Infect Dis
. 2018
;18
(4
):441
–51
. 28.
Ouldali
N
, Varon
E
, Levy
C
, Angoulvant
F
, Georges
S
, Ploy
MC
, et al. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study
. Lancet Infect Dis
. 2021
;21
(1
):137
–47
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
